Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 06
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
BioLife Solutions Inc
BLFS
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$39.00
0.39
1.01%
Dern. MÀJ: Oct 5, 4:15 PM
$39.00
0.39
1.01%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Fusions et acquisitions:
BioLife Solutions (BLFS) was acquired by Repligen (RGEN) on Tuesday, October 6, 2026 for $1.5B paid in cash & stock
BioLife Solutions Financials
BioLife Solutions (BLFS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
BioLife Solns Q2 Sales $28.466M Beat $27.683M Estimate
Benzinga Newsdesk
PRO
BioLife Solutions Affirms FY2026 Sales Guidance of $112.500M-$115.000M vs $112.942M Est
Benzinga Newsdesk
PRO
BioLife Solns Q1 Adj. EPS $0.04 Beats $0.02 Estimate, Sales $27.500M Beat $25.664M Estimate
Benzinga Newsdesk
BioLife Solutions Earnings Report: Q4 Overview
Benzinga Insights
PRO
BioLife Solutions Sees FY2026 Sales $112.500M-$115.000M vs $111.058M Est.
BioLife Solutions (NASDAQ:BLFS) sees FY2026 sales of $112.500 million-$115.000 million vs $111.058 million analyst estimate.
Benzinga Newsdesk
PRO
BioLife Solns Q4 Adj. EPS $0.04 Beats $(0.02) Estimate, Sales $24.764M Beat $24.082M Estimate.
BioLife Solns (NASDAQ:BLFS) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.02) by 281.82 percent. This is a 300 percent increase over losses of $(0.02) per share from the
Benzinga Newsdesk
